BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38709344)

  • 1. Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis.
    Brunson C; Struycken L; Schaub D; Ref J; Goldberg D; Hannallah J; Woodhead G; Young S
    Abdom Radiol (NY); 2024 May; ():. PubMed ID: 38709344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
    Pal Chaudhary S; Reyes S; Chase ML; Govindan A; Zhao L; Luther J; Bhan I; Bethea E; Franses JW; Paige Walsh E; Anne Dageford L; Kimura S; Elias N; Yeh H; Markman J; Bozorgzadeh A; Tanabe K; Ferrone C; Zhu AX; Andersson K; Thiim M; Antonio Catalano O; Kambadakone A; Vagefi PA; Qadan M; Pratt D; Hashemi N; Corey KE; Misdraji J; Goyal L; Clark JW
    Oncologist; 2023 Apr; 28(4):341-350. PubMed ID: 36763374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
    Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
    JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
    Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis.
    Billeter AT; Müller PC; Albrecht T; Roessler S; Löffler M; Lemekhova A; Mehrabi A; Müller-Stich BP; Hoffmann K
    J Gastrointest Surg; 2021 May; 25(5):1193-1202. PubMed ID: 32378092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works.
    Eguchi Y; Wong G; Lee IH; Akhtar O; Lopes R; Sumida Y
    Hepatol Res; 2021 Jan; 51(1):19-30. PubMed ID: 33091191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma.
    Hernandez-Alejandro R; Croome KP; Drage M; Sela N; Parfitt J; Chandok N; Marotta P; Dale C; Wall W; Quan D
    World J Gastroenterol; 2012 Aug; 18(31):4145-9. PubMed ID: 22919246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.
    Kim MA; Jang H; Choi NR; Nam JY; Lee YB; Cho EJ; Lee JH; Yu SJ; Kim HC; Chung JW; Yoon JH; Kim YJ
    J Hepatocell Carcinoma; 2021; 8():1565-1577. PubMed ID: 34909425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease.
    Zachou K; Azariadis K; Lytvyak E; Snijders RJALM; Takahashi A; Gatselis NK; Robles M; Andrade RJ; Schramm C; Lohse AW; Tanaka A; Drenth JPH; Montano-Loza AJ; Dalekos GN;
    JHEP Rep; 2023 Aug; 5(8):100778. PubMed ID: 37456672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma.
    Yoon JS; Lee HY; Chung SW; Kim SW; Chang Y; Lee YB; Cho EJ; Lee JH; Yu SJ; Kim H; Yoon JH; Kim YJ
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1960-1968. PubMed ID: 32128882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
    Hiraoka A; Kumada T; Tada T; Tani J; Kariyama K; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Aoki T; Tanaka T; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Arai T; Okubo T; Imai M; Koizumi Y; Nakamura S; Joko K; Hiasa Y; Kudo M;
    Sci Rep; 2021 Aug; 11(1):16663. PubMed ID: 34404856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
    Di Maira G; Foglia B; Napione L; Turato C; Maggiora M; Sutti S; Novo E; Alvaro M; Autelli R; Colombatto S; Bussolino F; Carucci P; Gaia S; Rosso C; Biasiolo A; Pontisso P; Bugianesi E; Albano E; Marra F; Parola M; Cannito S
    J Pathol; 2022 May; 257(1):82-95. PubMed ID: 35064579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).
    Stepanova M; Rafiq N; Makhlouf H; Agrawal R; Kaur I; Younoszai Z; McCullough A; Goodman Z; Younossi ZM
    Dig Dis Sci; 2013 Oct; 58(10):3017-23. PubMed ID: 23775317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
    Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
    J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
    Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
    Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.
    Lin BZ; Lin TJ; Lin CL; Liao LY; Chang TA; Lu BJ; Chen KY
    J Chin Med Assoc; 2021 Jun; 84(6):606-613. PubMed ID: 33871391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
    Reddy SK; Steel JL; Chen HW; DeMateo DJ; Cardinal J; Behari J; Humar A; Marsh JW; Geller DA; Tsung A
    Hepatology; 2012 Jun; 55(6):1809-19. PubMed ID: 22183968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data.
    Wong RJ; Chou C; Bonham CA; Concepcion W; Esquivel CO; Ahmed A
    Clin Transplant; 2014 Jun; 28(6):713-21. PubMed ID: 24654688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.